
Business
Business Brief: Argent Biopharma’s Revenues Drop, Outgoings Rise Ahead of AusCann Deal
Argent Biopharma, formerly MGC Pharmaceuticals, has entered 2026 in a precarious financial position, according to its recently published quarterly figures.
